Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains

EU orphan designation number: EU/3/17/1863   
Active ingredient: Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains
Indication: Treatment of multiple myeloma
Sponsor: Celgene Europe B.V.
Winthontlaan 6 N, 3526 KV Utrecht, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/04/2017 Orphan designation EMA/OD/270/16 (2017)2782 of 20/04/2017
16/10/2017 Transfer of orphan designation EMA/OD/270/16/T/01 (2017)7024 of 13/10/2017
13/11/2018 Transfer of orphan designation EMA/OD/270/16/T/02 (2018)7574 of 9/11/2018